MPN ASH 22
Symptom-related quality of life is linked with the type of cytoreductive treatment used for MPNs.
TP53 and complex karyotype are very high-risk factors in patients with myelofibrosis undergoing HSCT.
The combination of ruxolitinib and pegylated IFNα2a showed significant reductions in spleen length.
BMS-986158 combined with ruxolitinib or fedratinib reduced spleen volume in patients with myelofibrosis.
Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis.
The combination of interferon and ruxolitinib may be a treatment option for newly diagnosed polycythemia vera.
Momelotinib led to an increased likelihood of becoming transfusion-independent compared with danazol in myelofibrosis.
Long-term follow-up results of a phase II study of ruxolitinib in patients with MPNs were presented at the 2022 ASH Meeting.
New data support the use of ropeginterferon alfa-2b therapy in patients with low-risk or high-risk PV,
An analysis of patients with MF found that the combination of navitoclax and ruxolitinib reduced MF-associated splenomegaly.
IFNα2 treatment may help reduce the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms ...
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.